Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

EVOK stock opened at $4.10 on Monday. The stock has a market capitalization of $3.36 million, a price-to-earnings ratio of -2.24 and a beta of 0.38. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $18.60. The business’s fifty day moving average price is $5.45 and its two-hundred day moving average price is $6.09.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). The company had revenue of $2.55 million for the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.